CSL Limited Sponsored ADR (CSLLY)
OTC PINK OTC PINK Primary Summary
CSL Limited (CSLLY) Analyst/Investor Day Prepared Remarks Transcript
CSL Limited (OTCQX:CSLLY) Analyst/Investor Day November 4, 2025 6:00 PM EST Company Participants Fiona Mead - Company Secretary & Head of Corporate Governance Paul McKenzie - MD, CEO & Executive Director Dave Ross - Senior VP & GM of Seqirus Presentation Fiona Mead Company Secretary & Head of Corporate Governance Hello. I'm Fiona Mead, CSL's Company Secretary.
CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript
CSL Limited (OTCQX:CSLLY) Q4 2025 Earnings Conference Call August 18, 2025 8:00 PM ET Company Participants Andy Schmeltz - Executive Vice President of CSL Behring Chris Cooper - Head of Investor Relations Herve Gisserot - Senior VP & GM of Vifor Joy Carolyn Linton - Chief Financial Officer Paul F. McKenzie - MD, CEO & Executive Director Conference Call Participants Andrew Goodsall - MST Financial Services Pty Limited, Research Division Andrew Paine - CLSA Limited, Research Division Craig Wong-Pan - RBC Capital Markets, Research Division David A.
CSL Limited (CSLLY) Q2 2025 Earnings Call Transcript
CSL Limited (OTCQX:CSLLY) Q2 2025 Results Earnings Conference Call February 10, 2025 7:00 PM ET Company Participants Chris Cooper - Vice President and Head of Investor Relations Paul McKenzie - Chief Executive Officer and Managing Director John Levy - Interim Chief Financial Officer Joy Linton - Interim Executive Vice President, CSL Behring Dave Ross - Senior Vice President and General Manager, CSL Seqirus Hervé Gisserot - Senior Vice President and General Manager, CSL Vifor Conference Call Participants Lyanne Harrison - Bank of America Davinthra Thillainathan - Goldman Sachs David Stanton - Jefferies David Low - J.P. Morgan Andrew Goodsall - MST Marquee Sacha Krien - Evans & Partners Saul Hadassin - Barrenjoey Craig Wong-Pan - RBC Capital Markets Steve Wheen - Jarden Andrew Paine - CLSA Laura Sutcliffe - UBS Mathieu Chevrier - Citigroup Shane Storey - Wilsons Advisory and Stockbroking Limited Thomas Wakim - Bell Potter Securities David Bailey - Macquarie Securities Shane Ponraj - Morningstar Operator Thank you for standing by and welcome to the CSL Limited Half Year Financial Results.
CSL Limited Sponsored ADR (CSLLY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has CSL Limited Sponsored ADR ever had a stock split?
CSL Limited Sponsored ADR Profile
| Biotechnology Industry | Healthcare Sector | Dr. Paul F. McKenzie Ph.D. CEO | OTC PINK Exchange | 12637N204 CUSIP |
| AU Country | 32,698 Employees | 11 Mar 2025 Last Dividend | - Last Split | - IPO Date |
Overview
CSL Limited is a globally prominent biopharmaceutical and vaccine company with its roots firmly planted in Melbourne, Australia since 1916. The company has carved out a significant presence not only in its home country but also across vital markets in the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and beyond. CSL Limited operates with a strategic focus on research, development, manufacturing, marketing, and distribution of innovative biopharmaceutical and vaccine solutions. It is organized into three main segments: CSL Behring, CSL Seqirus, and CSL Vifor, each targeting specific healthcare needs worldwide. Additionally, CSL Limited actively engages in licensing its intellectual property, underscoring its contributions to advancing global healthcare technologies and treatments.
Products and Services
- CSL Behring
This segment caters to a variety of healthcare needs through its diverse portfolio of products. CSL Behring is renowned for its plasma products, contributing to therapies for immunodeficiencies and rare diseases. It also pioneers in gene therapies, offering cutting-edge treatments for genetic disorders. Furthermore, CSL Behring provides recombinant products, marking significant advances in biotechnology for therapeutic uses.
- CSL Seqirus
Specializing in influenza-related products, CSL Seqirus stands out for its proactive approach towards flu prevention and pandemic preparedness. It offers a breadth of seasonal flu vaccines, ensuring public health safety across the globe. Additionally, CSL Seqirus collaborates with governments worldwide, offering pandemic services and solutions aimed at combating influenza outbreaks efficiently and effectively.
- CSL Vifor
With a keen focus on iron deficiency and nephrology, the CSL Vifor segment advances medical treatments in these crucial therapeutic areas. By developing and distributing specialized products, CSL Vifor addresses a range of conditions related to kidney health and iron metabolism, providing essential solutions for patients suffering from these ailments.
Contact Information
